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Abstract 
The considerable heterogeneity of outcomes and measurement instruments in hand 
eczema trials substantially limits the evidence synthesis concerning therapeutic and 
preventive interventions. Therefore, the Hand Eczema Core Outcome Set (HECOS) 
initiative is developing a core outcome set for future trials. The first objective was to 
identify outcomes that were measured in previous trials, to group them in domains, and 
to identify their measurement instruments. We conducted a systematic review of 
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controlled and randomized controlled hand eczema trials published since 2000. Sixty-
one eligible studies were identified. Each assessed one or more out of 47 outcomes in 
the “skin” domain. Eighteen trials (30%) additionally focused on preventive behaviour in 
risk occupations. Quality of life was measured in 13 studies (21%). Thirty-two distinct 
named instruments were applied, but 223 measurements (62%) were conducted with 
unnamed instruments. Only 32 studies (52%) defined a primary outcome. Twenty-nine 
trials (48%) provided some information on adverse events but none gave any references 
concerning relevant methods. Our review confirms the need to harmonize outcome 
measurements in hand eczema trials. The findings are the basis for a consensus 
process to generate a core outcome set to improve the explanatory power and 
comparability of future hand eczema studies. 
 
Keywords: Core Outcome Set, CSG-COUSIN, Hand Dermatitis, Outcome 
Measurement Instruments  
 














1.  Introduction 
Hand eczema is a complex, multifactorial and impairing skin disease. With a one-year 
prevalence of nearly 10% it is common in the general population (1). Moreover, 
occupational hand eczema is one of the most common occupational diseases and 
constitutes 40% of all occupational diseases in industrialized nations causing substantial 
psychological and economic burden for affected individuals and society (2,3,4,5).  
Considerable research efforts are therefore undertaken in order to develop and 
evaluate interventions aiming to prevent the development, recurrence or worsening of 
hand eczema, or to ease its burden. However, trials studying these interventions use a 
variety of outcomes to determine their success. The problems arising from such 
heterogeneity have been explained in detail by the Core Outcome Measures in 
Effectiveness Trials (COMET) initiative (6). In short, heterogeneity considerably limits the 
comparability and overall confidence in the study results, and thereby the strength of 
recommendations for clinical practice (7). To help overcome these problems, the Hand 
Eczema Core Outcome Set (HECOS) initiative was formed. This international working 
group of dermatologists and researchers experienced in hand eczema trials aims to 
develop a core outcome set for standardized evaluation of therapeutic and preventive 
interventions in future hand eczema trials and reviews. This core outcome set will define 
the minimum that should be measured and reported in interventional trials of hand 
eczema (8). Apart from enhancing the methodological quality, comparability, and 
usefulness of hand eczema trials for clinical decision-making, the COS will also 
considerably reduce the effort of planning, conducting, and reporting individual hand 
eczema studies as well as reviews and meta-analyses. The methodology of HECOS will 













follow the guidance provided by the Cochrane Skin Group Core Outcomes Set Initiative 
(CS-COUSIN) (9,10).  
As an early step in the core outcome set development, we systematically 
reviewed controlled or randomized controlled hand eczema trials published since 2000, 
covering all types of participants, interventions, and comparisons. We aimed to identify 
the outcomes they measured (e.g. “itch”), to group relatively similar outcomes in 
domains (e.g. “skin”), and to specify the instruments that were applied to measure them 
(e.g. “visual analogue scale”). This overview will facilitate the HECOS consensus 
process by providing an overview of relevant outcomes and instruments to be 
considered for the core outcome set. 
2.  Methods 
The review was conducted according to an unpublished protocol. 
2.1  Explanation of terms 
No distinction was made between efficacy and effectiveness outcomes. We 
distinguished between outcomes, outcome domains, outcome measurement 
instruments, and measurements. Outcomes specify what is measured: hand eczema 
trials report, for instance, the presence of hand eczema, or the extent of skin dryness or 
erythema. Outcome domains are categories of outcomes that are similar in content, e.g. 
the categories “skin” or “social functioning”. Outcome measurement instruments on the 
other hand specify how an outcome is measured: The presence of hand eczema, for 
example, may be measured by applying diagnostic criteria developed by the study 
researchers or by pre-existing instruments such as certain items of the Nordic 
Occupational Skin Questionnaire (11). The number of measurements, in our context, 
means how often outcomes were measured across trials. If, for instance, 10 trials 













measure transepidermal water loss (TEWL) (12), this adds up to 10 measurements of 
one outcome. This distinction is important for this review because relevant properties 
(like who assesses the outcome) apply to measurement instead of outcome level. 
2.2  Search methods 
In May 2017, we performed a systematic literature search in Ovid Medline and Embase. 
Additionally, references of overview articles that were identified during this process as 
well as hand-eczema-related systematic reviews published in the Cochrane library were 
searched. We further looked for protocols of eligible ongoing hand eczema trials in 
relevant clinical trials registries. The search terms are given in Supplemental Table 1. 
We included controlled and randomized controlled clinical hand eczema trials 
published in English or German since January 1, 2000, covering all types of participants, 
interventions (including preventive interventions), and comparisons. Retrospective or 
observational studies without intervention, laboratory experiments, and conference 
abstracts were excluded. Study eligibility was assessed independently by two 
investigators per record based on titles and abstracts. When this was not possible, full 
texts were obtained and evaluated. All differences were dissolved by discussion, 
involving a third investigator when needed. 
2.3  Data extraction 
Full texts were obtained for all eligible studies. A data extraction template (including 
guidance for its use) was developed and pretested. All relevant information was 
extracted independently by two researchers for each trial: Study details, data on efficacy 
/ effectiveness outcomes, data on safety outcomes, and baseline characteristics. 
Discrepancies were resolved by discussion and in case of conflict a third investigator 
was involved.  













Reported outcomes that were not specified in the article’s methods section 
were included as well. All efficacy and safety outcomes were extracted, even when 
considered unrelated to hand eczema. Control variables / factors were not extracted. 
The identified efficacy outcomes were mapped according to the taxonomy developed by 
the Core Outcome Measures in Effectiveness Trials (COMET) initiative (13). In 
accordance with this taxonomy, clinical signs as well as symptoms were classified within 
the “physiological or clinical” core area. Composite outcomes addressing several 
domains were classified within each of the covered domains. 
3.  Results 
3.1  Included studies 
 
Figure 1: PRISMA flow diagram adapted from Moher et al (14)  














After removing duplicates, we identified and screened 938 potentially eligible records 
(Fig. 1). Twenty-four of these articles were written in languages other than English or 
German and were therefore excluded. Two of them (1 Turkish and 1 Polish) were 
potentially eligible (apart from the language criterion), judging from their abstracts. Most 
studies were conducted in Europe (Table 1). Finally, 16 non-randomized, 41 
randomized, and 4 ongoing randomized studies were included (Supplemental Table 2). 













Fifty-nine per cent of the trials investigated therapeutic interventions while 38% 
assessed preventive interventions. Two studies (3%) provided no clear indication 
whether their intervention was therapeutic or preventive. The severity of the study 
populations’ hand condition varied considerably, ranging from participants with healthy 
skin (in prevention studies) to patients with severe chronic hand eczema. 
Several studies evaluated complex interventions (e.g. recommendations to apply 
various protective measures). It was therefore impossible to derive actual counts from 
our database. However, more than half of the trials investigated topical treatments and 
about one third evaluated skin protection education, training or counselling. Around 10% 
investigated oral treatments or phototherapy, respectively. Hand cleansing and glove 
use were specifically investigated in one trial each and were part of an unknown number 
of complex interventions. One trial investigated the effects of a nickel-reduced diet in 
nickel-sensitive hand eczema patients. 
The following study characteristics apply to the studies for which they were 
reported: A total of 12620 participants were recruited, ranging from 8 to 1649 per study. 
The average participants’ age per study ranged from 17 to 55 years. More women than 
men were included (62% female, unweighted mean). 
3.2  Efficacy / effectiveness outcomes and outcome measurement instruments 
Thirty-two studies defined a primary outcome (25% of CCTs and 62% of RCTs); 26 of 
them defined one and the remaining trials up to 5 primary outcomes. More recent trials 
were more likely to define a primary outcome: From 2009 to 2016, 70% of the trials 
defined a primary outcome as compared to 42% of the trials published from 2000 to 
2008 (Fisher's Exact test: P = 0.06). Each study conducted between 1 and 28 
measurements (mean = 3.8 in therapeutic and 9.7 in prevention trials), amounting to a 













total of 360 measurements. Two hundred twenty-three measurements applied unnamed 
instruments (54% in therapeutic and 67% in prevention trials). The remaining 137 
measurements were conducted with 32 distinct instruments (25 in therapeutic and 17 in 
prevention trials).  
 
Figure 2: Outcome domains of efficacy outcomes categorized according to Dodd et al. 
(13) 
▪ number of measurements in therapeutic trials; ▪ number of measurements in 
prevention trials; ▪ number of trials; ▪ number of trials with this primary outcome 
Empty domains are not displayed. 
 
 
3.3  “Skin” domain 
Most outcomes, by far, were measured in the “skin” domain (all 61 trials, see Fig. 2). In 
accordance with the taxonomy, this domain covers physiological / clinical skin outcomes 
including physiological function, signs, and symptoms. Forty-seven skin outcomes were 
assessed in hand eczema trials (Table 2). 
The most often applied outcome measurement instrument in the skin domain was 
an item of the Dermatology Quality of Life Index (DLQI; “Over the last week, how itchy, 
sore, painful or stinging has your skin been?”; 10 trials) but this was not reported as a 
separate outcome. The Hand Eczema Severity Index (HECSI) was applied in 6 and 













Tewameter measurements in 8 trials. Other outcomes were assessed in less than 10% 
of the trials (Supplemental Table 3).  
3.4  “Delivery of care” domain 
The second largest domain was “delivery of care”, in particular the sub-domain 
“adherence / compliance”. This sub-domain was important in prevention trials in 
occupations with particular risk of developing hand eczema. There, it referred to skin 
protective behaviour of the employees (18 trials) and preventive measures provided by 
the employer (5 trials). A list of all 72 non-skin outcomes is provided in Supplemental 
Table 4. 
3.5  “Functioning” and other domains 
The domains “physical functioning” (13 trials), “social functioning” (12 trials), and 
“emotional functioning / wellbeing” (13 trials) addressed e.g. fatigue, affectedness of 
physical or social activities, or embarrassment and were measured only as part of a 
health-related quality of life (HRQOL) questionnaire. “Cognitive functioning” (11 trials) 
was either measured as part of a health-related quality of life (HR-QoL) questionnaire 
(e.g. worries about hand eczema) or referred to preventive knowledge. The domain “role 
functioning” was evaluated in 16 trials. It always referred to the participant’s ability to 
work or study and was assessed as part of a HR-QoL questionnaire (7 trials), as an 
outcome of its own (3 trials), or both (6 trials). All other domains were covered by few 
studies (Fig. 2). 
3.6  Properties of the outcome measurements 
Out of the total of 360 measurements, a vast majority of 195 were patient-reported (33% 
of the measurements conducted in therapeutic trials and 69% of the measurements in 













prevention trials). Sixty-two measurements were performed by physicians, 8 by other 
study personnel, and 19 were patient-reported as well as assessed by a physician or 
other personnel. Two laboratory measurements, 24 skin-physiological measurements 
(e.g. skin hydration), and 6 other measurements with technical devices (e.g. L-a-b 
histogram, skin contrast) were performed. For 46 measurements, the information was 
lacking in the study reports. The proportion of studies that included at least one (partly) 
patient-reported outcome was 74%. It varied from year to year without a clear tendency 
(71% from 2000 to 2008; 78% from 2009 to 2016; Fisher's Exact test: P = 0.76). Overall, 
some reference was provided for 161 of the 360 measurements, implying that the 
instruments had been used before. However, only 102 referred to development or 
validation studies or to guidelines for the use of the instruments.  
3.7  Safety outcomes 
Thirteen trials reported their methods to detect adverse events. Six of these methods 
were unspecified (e.g. stating that adverse events were recorded). Another 16 trials 
reported adverse events without mentioning their methods to detect them. None of the 
studies gave any references concerning methods of registering adverse events.  
4.  Discussion 
To our knowledge, this is the first systematic review that summarizes the use of 
outcomes and outcome measurement instruments in hand eczema trials. It is part of the 
HECOS initiative and will be the basis for developing a core outcome set for future hand 
eczema trials. Sixty-one eligible studies were identified.  













4.1  Outcomes in the “Skin” and other domains 
Not surprisingly, the majority of all measurements were conducted within the “skin” 
domain. However, 47 distinct skin outcomes were measured, encompassing various 
symptoms such as itch or pain, clinical signs like vesicles or scaling, overall ratings of 
hand eczema severity or extent, and parameters with unclear relevance for hand 
eczema like skin surface pH or skin contrast. The complete list of these outcomes will be 
used in a Delphi survey to determine which are considered crucial by patients, clinicians, 
investigators, and other stakeholders. Other domains were investigated mainly to 
evaluate the participants’ HRQOL, their ability to work, and outcomes related to the 
prevention of occupational hand eczema. The outcomes will be considered in the Delphi 
survey.  
4.2  Differences between therapeutic and prevention trials 
In the “skin” domain, half of the outcomes were measured in therapeutic as well as in 
prevention trials. For the remaining outcomes (with the exception of “ever had hand 
eczema”), no reason was apparent why these outcomes should not be eligible for both 
types of study. Prevention trials conducted more than twice as many measurements per 
trial and the proportion of patient-reported outcomes was twice as high compared to 
therapeutic trials. Prevention trials also applied more unnamed instruments.  
Most of the additional outcomes belonged to the domain “delivery of care”, in 
particular the uptake of protective behaviour and the status of skin protection at the 
workplace. These intermediate outcomes do not directly benefit the patient. Instead, it is 
expected that they are associated with physiological outcomes. Since 38% of the trials 
addressed prevention strategies, an extended core outcome set will probably be 













necessary for prevention trials, which will be considered in the consensus process to 
identify core outcomes.  
4.3  Outcome measurement instruments 
Each of the 32 named outcome measurement instruments was applied in only a minority 
of studies. The most frequent were the DLQI in 16%, Tewameter measurements in 13%, 
and the HECSI in 10% of the trials. In addition, the majority of outcomes were measured 
without referring to any development or validation studies of the respective instruments. 
Beyond that, however, we did not yet explore to which extent the instruments were 
validated. This will be the next step of HECOS and topic of a separate publication. Apart 
from the validity of the instruments, it remains unclear how far they may be comparable 
to each other. This concerns in particular the assessment of skin impairment, for which a 
large number of instruments were applied. Across other domains as well, unnamed 
instruments, predominantly questionnaires, were applied more than twice as often as 
named instruments. 
4.4  Safety outcomes 
While an in-depth analysis of the applied safety outcomes will be covered in another 
publication, it is already apparent that none of the included studies provided any 
references concerning safety outcomes. The Patient-Reported Outcomes Safety Event 
Reporting (PROSPER) Consortium Guidance provides insight on how to gather such 
outcomes (15). This process involves validating the instruments that measure safety 
outcomes, which so far has not been reported for any of the included hand eczema 
trials. Complementary, more specific guidance on clinician-reported safety outcomes is 
needed for hand eczema studies. The US National Institutes of Health Ongoing Trials 
Register offers detailed advice on how to report safety outcomes (16). HECOS will 













provide guidance on how to collect such data with validated instruments in hand eczema 
trials.  
4.5  Outcome taxonomy 
A recent review by Dodd et al (13) revealed that despite availability of a variety of 
outcome taxonomies, none of them was sufficient for categorizing the outcomes of all 
clinical trials. They developed a new taxonomy, which proved to be very suitable for 
categorizing the outcomes identified in our review. It is structured by 5 core areas and 
domains within these areas and also provides a comprehensive guidance on how to 
map outcomes accordingly. Most outcomes that were identified by our review could be 
fitted into exactly one of the domains. Only HR-QoL outcomes were difficult to map 
because the taxonomy requires categorizing composite outcomes within each domain 
covered by their components and some individual questionnaire items did not fit the 
domains well. In the DLQI (17), for example, the first question (“Over the last week, how 
itchy, sore, painful or stinging has your skin been?”) was considered as an item that 
addresses skin symptoms and was therefore classified in the “skin” domain. If the item 
had a slightly different wording (like “How much did you suffer from itchy, sore, painful or 
stinging skin?”), it would cover the “emotional functioning/well-being” category instead. 
For another DLQI question (“Over the last week, how much has your skin influenced the 
clothes you wear?”), no category was completely appropriate – the question may refer to 
social or emotional functioning, or neither. While we agree with Dodd et al that it is 
important to identify the content of score components for some purposes, this may not 
be necessary for many other objectives. Composite scores are designed to measure 
constructs (like HR-QoL) as a whole and we therefore consider that it would be 
appropriate to categorize them at construct level. Also, the categorization process would 













be simpler and would result in less variability between raters. In this review, however, 
composite outcomes were categorized at component level as proposed by the taxonomy 
developers. This approach was accompanied by the uncertainties described above for 
HR-QoL scores, but other composite outcomes were not affected because all of their 
components fell into the “skin” domain. 
4.6  Strengths and limitations 
Our review has some limitations. Firstly, it was restricted to articles published since 2000 
in English or German language. Thus, outcomes and measurement instruments that 
were exclusively published in older articles or other languages were not considered. 
However, only two additional articles would have been eligible without the language 
restriction. Secondly, we were unable to assess how many of the unnamed instruments 
were actually identical. The photographic guide developed by Coenraads et al (18), for 
instance, was used in several studies, but from the data gathered it was impossible to 
determine the exact number. Other outcomes, like various 3-point scales of skin 
impairment, appeared similar but also lacked a name to clarify if they were identical or 
not. A strength of this review was that the databases were searched intensely for all 
eligible trials and all data were extracted in duplicate with a pretested template so that 
we are confident that all contemporary hand eczema outcomes and outcome 
measurement instruments were covered in this review insofar they were applied in 
controlled trials. 
5.  Conclusion 
This review provides an overview of efficacy / effectiveness outcomes that have been 
applied in interventional hand eczema trials since 2000. Our findings confirm the need 













for harmonizing outcome measurement instruments and for promoting the usage of 
validated instruments.  
The results of the review are the basis for a consensus process to generate a 
core outcome set. In the course of the project, the core outcome set is going to be 
completed by determining appropriate, validated measurement instruments for each 
relevant domain. This systematic review ensures that all previously applied outcomes 
will be considered in this process. As a result of this harmonization, the explanatory 
power and comparability of future hand eczema trials will be improved considerably. 
Researchers who are planning new hand eczema trials are invited to visit the 
HECOS website for updates. Scientists, clinicians, and patients who wish to participate 
in HECOS are encouraged to contact us.  
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Table 1: Geographic setting of the studies 
 
Therapeutic trials Prevention trials 
  
Number 
of trials Percent 
Number 
of trials Percent 
Germany 6 10% 11 18% 
USA 6 10% 2 3% 
Denmark 3 5% 5 8% 
The Netherlands 5 8% 0 0% 
UK 0 0% 2 3% 
Iran 3 5% 0 0% 
India 3 5% 0 0% 
other* 10 16% 3 5% 
* Belgium, Canada, Estonia, Finland, France, Greece, 
Hungary, Israel, Italy, Norway, Poland, Switzerland, 
Turkey 
 



















aching, pain, sore skin, tenderness x x 
breaks in the skin, fissures, fissuring, cracking, cracks, rhagades, splits, cuts x x 
burning x x 
coarseness, roughness x x 
crusting, crusts, serum crusting x x 
desquamation, scaling, flaking, squamation x x 
dryness, dry skin x x 
dyshidrosis, vesicles, vesiculation, tiny water blisters x x 
erythema, reddening, redness x x 
ever had hand eczema x x 
general change of hand eczema x x 
general hand eczema severity x x 
general improvement of hand condition x x 
infiltration x x 
irritated skin x x 
itch, itching, pruritus x x 
lichenification, thickened skin x x 
number of eruptions during past 3 months x x 
oedema, edema, swelling x x 
papulation, papules, red papules x x 
skin capacitance, moisture, skin hydration x x 
time to relapse x x 
trans-epidermal water loss (TEWL), barrier function x x 
area affected, general extent of hand eczema x 
 furrowing, lined skin x 
 hyperkeratosis, hyperkeratoses x 
 impairment of mobility x 
 induration x 
 inflammation x 
 oxidative stress x 
 prurigo nodules x 
 scratching x 




erosions, abrasions, excoriation, excoriations 
 
x 
ever had eczema on wrists or forearms 
 
x 
last episode of hand eczema 
 
x 















skin surface pH 
 
x 









thin skin   x 
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